Tracking outcomes for chronic blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This study follows people with certain chronic blood cancers to understand how the diseases progress and how treatments affect outcomes over time. It may help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years old or older.
- You must have one of these conditions: polycythemia vera, essential thrombocythemia, or a type of myelofibrosis.
- You must have been followed by the study team for at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
This study follows people with high red blood cell counts (erythrocytosis) who are seen at a blood specialty clinic. The goal is to track their health over time to learn more about this condition and how it affects patients.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
This is a research registry for people who have certain blood cancers called myeloproliferative neoplasms (MPNs). It helps researchers learn about the disease over time and may help future studies find and compare patients.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.